David Fu
Optometrist · Houston, TXNPI 1417270307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $753, 3.3 times the $229 reported in 2019.
Across 167 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$808
- Sun Pharmaceutical Industries Inc.$449
- Glaukos Corporation$437
- Tarsus Pharmaceuticals, Inc.$278
- Bausch & Lomb Americas Inc.$268
- Bausch & Lomb, A Division Of Bausch Health US, LLC$208
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,017100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $808 |
| Sun Pharmaceutical Industries Inc. | 21 | $449 |
| Glaukos Corporation | 7 | $437 |
| Tarsus Pharmaceuticals, Inc. | 11 | $278 |
| Bausch & Lomb Americas Inc. | 13 | $268 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $208 |
| Oyster Point Pharma, Inc. | 9 | $179 |
| Aerie Pharmaceuticals, Inc. | 6 | $133 |
| Kala Pharmaceuticals, Inc. | 7 | $130 |
| Harrow Eye, LLC | 4 | $119 |
| AstraZeneca | 4 | $116 |
| Alcon | 5 | $104 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $98 |
| Amgen(2 entities) | 4 | $94 |
| UCB, Inc. | 3 | $85 |
| Novartis | 4 | $83 |
| Biotissue Holdings Inc. | 4 | $77 |
| Thea Pharma Inc. | 3 | $67 |
| Merz North America, Inc. | 3 | $58 |
| Akorn Operating Company LLC | 3 | $57 |
| Dompe US, Inc. | 1 | $33 |
| Catalyst Pharmaceuticals, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $28 |
| Argenx US, Inc. | 1 | $28 |
| Celularity Inc. | 1 | $17 |
| Rxsight Inc | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$139
- Photrexa$139
How this compares
$4,017 in reported general payments places this provider in the 85th percentile of 4,315 optometrist providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 76 | $44,976 |
| VyzultaLatanoprostene Bunod | 37 | $13,547 |
| RestasisCyclosporine | 13 | $10,541 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,146 |
| Prednisolone Acetate | 219 | $9,002 |
| Travoprost | 27 | $5,483 |
| Bimatoprost | 28 | $3,446 |
| Latanoprost | 318 | $3,242 |
| Loteprednol Etabonate | 28 | $2,855 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 206 | $2,759 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,634 |
| Brimonidine Tartrate | 101 | $1,763 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,561 |
| Difluprednate | 20 | $1,547 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $808 | $64,663115 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $268 | $13,54737 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $208 | $2,85528 claims |
| AlconSimbrinza | $104 | $2,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Maria WalkerHouston$128K
- Seema NandaHouston$87K
- Danica MarrelliHouston$87K
- Richard BakerHouston$78K
- Karen LeeHouston$71K
- Nishi MehdirattaHouston$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.